Skip to main content
Thursday 19 November 2026
BlueSky linkedin youtube
header links
  • Get Newsletters
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Equity and Sustainability
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Rare Disease
    • GLP-1
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO
    • BIO-Europe
    • C-Suite Innovators
    • ESMO
    • Frontiers Health
    • JP Morgan
    • Global Policy Insights
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
youtube linkedin BlueSky
Sign in

central nervous system

News
idorsia-building-04--highres

Neurocrine signs $400M-plus deal with Idorsia for epilepsy d...

News
A sad young woman is sitting in her kitchen with a headache

Allergan builds case for migraine drug ubrogepant as FDA ver...

News
Spravato

J&J seeks wider use of its Spravato antidepressant in US

News
Concept of memory loss and brain aging due to dementia and alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves with 3D illustration elements.

Last BACE bombs: Eisai, Biogen give up on elenbecestat

News
Closeup of X-ray photography of human brain

Tocagen plummets on phase 3 data for glioma therapy

News
Lilly firms up case for Emgality in migraine market chase

Lilly firms up case for Emgality in migraine market chase

  • Load more results

Editor's Picks

  1. Boehringer forges $7bn alliance with China's SBP Group News
  2. Lilly partners with Hims & Hers on obesity drug sales
  3. UK women's health firm Theramex sold for around £2.2bn
  4. What do midterms mean for Trump's pharma and health agenda?
  5. NICE backs Keytruda/Padcev combo for bladder cancer
News
MSD stops trials of BTK inhibitor for blood cancers

MSD stops trials of BTK inhibitor for blood cancers

MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png
Sales & Marketing
Securing your ROI: Turning post-acquisition integration into operational and strategic value
Sponsored

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • Axtria Ignite 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Get Newsletters

 
 
youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company